Alirocumab AdComm Net Positive for Esperion Therapeutics (ESPR) ETC-1002, Needham & Company Says
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/8/2026
- S&P 500 falls as AI worries hit software makers
- Brent crude hits six-week high near $97 as Houthi strike targets Saudi Aramco
- Qualcomm stock surges 9.5% on Amazon AI deal & 25M share warrant
- Energy stocks rise premarket as oil prices climb on Middle East supply fears
- Novartis shares plunge 10% as failed drug trial clouds growth outlook
- Harry and Meghan surprised by King Charles' letter on their status
- Citi initiates UiPath coverage with Buy rating and $23 target
- S&P 500 falls as AI worries hit software makers
- WestPark Capital Starts Akebia Therapeutics (AKBA) at Buy
- After an 18% summer selloff in chip stocks, Citi asks what comes next
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Esperion Therapeutics (ESPR) Has Notable New Fan at the FDA and Should Be Bought on Weakness - Barclays
June 11, 2015 2:21 PM EDTAfter losing 19% Wednesday amid labeling and other concerns arising from the PCSK9 FDA AdCom panel discussion, weakness in Esperion Therapeutics (NASDAQ: ESPR) is continuing today with stock off another 2.6%. Despite the weak stock action, many sell-side analysts have come out to defend the name. Barclays was the latest, and today brought with... More
Credit Suisse Defends Esperion Therapeutics (ESPR); Does Not See Impact from PCSK9 Panel
June 10, 2015 1:06 PM EDTCredit Suisse is the latest firm to come out in defense of Esperion Therapeutics (NASDAQ: ESPR), which fell more than 20% today following the PCSK9 panel discussion yesterday, which some viewed as cautious for the label.
Analyst Jeremiah Shepard said they do not... More
Esperion Therapeutics (ESPR) Price Target Lowered to $50 at Chardan
June 10, 2015 10:06 AM EDTChardan Capital Markets maintained a Sell rating on Esperion Therapeutics (NASDAQ: ESPR) and lowered its price target to $50.00 (from $55.00). The change follows an FDA panel meeting and vote supporting approval of Regeneron's (NASDAQ: REGN) Praluent. Analyst Gbolahn Amusa... More
Esperion Therapeutics (ESPR) Weakness Overdone Amid FDA AdCom on SNY/REGN's Praluent, UBS Says
June 10, 2015 7:56 AM EDTUBS analyst Andrew Peters maintained a Buy rating and price target of $140 on Esperion Therapeutics (NASDAQ: ESPR) saying they see a modest impact from the narrowed AdCom vote, discussion. Despite ultimately voting for approval, panellists at today's FDA AdCom on SNY/REGN's Praluent appeared... More
Esperion (ESPR), Amgen (AMGN) Shares Weaken Post-Market After Praluent Gets FDA Backing
June 9, 2015 5:39 PM EDT(Updated - June 9, 2015 5:49 PM EDT)
Esperion Therapeutics (NASDAQ: ESPR) shares declined after-hours Tuesday. Earlier an FDA panel voted to back Regeneron (NASDAQ: REGN) and Sanofi's (NYSE: SNY) PCSK9, Praluent. Shares of Amgen (NASDAQ: AMGN) are also trading down slightly.
... More